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Abstract 
The recent discovery that the major histocompatibility complex of class I (MHC I) expression 
has a role in the synaptic elimination process, represented an insight into understanding the 
cross talk between neurons. In the present study, the possibility that glatiramer acetate (GA) 
treatment influences the MHC class I expression and the synaptic plasticity process in the 
spinal cord during the course of EAE was investigated. C57BL/6J mice were induced to EAE 
and submitted to treatment either with a placebo solution or with GA (0.05mg/animal, 
subcutaneously, on a daily basis). All the animals were sacrificed at the peak disease (14 days 
after induction) or at the point of recovery of the clinical signs (21 days after induction). The 
spinal cords were removed and submitted to immunohistochemical examination, Western 
blotting and transmission electron microscopy analysis. The results showed that GA treat-
ment was able to decrease synaptic loss during the course of EAE, which correlates with the 
downregulation of the MHC I complex. The present results reinforce the neuroprotective 
role of GA treatment, by reducing synaptic loss during the course of the disease. Such action 
may be associated with the recently described role of MHC I regulation during the synaptic 
plasticity process. 
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Introduction 
Spinal  motoneurons  represent  the  final  motor 
pathway connecting the central nervous system to the 
muscle. Their cell bodies are located in the CNS terri-
tory and possess numerous dendrites that extend for 
several micrometers within the lamina IX. Dendrites 
receive a massive number of inputs which are finely 
selected  during  development  and  maintained 
throughout the life span. The cell bodies also receive a 
number of inputs, which are thought to have major 
influence on deflagration of the action potential [1]. 
 Although  the  morphological  features  and  ar-
chitecture of the spinal cord have been well known for 
several  decades,  how  the  organization  of  so  many 
synapses  is  achieved  and  maintained  throughout 
adulthood,  and  how  motoneurons  select  the  inputs 
that should be kept or eliminated under different sit-
uations is still obscure [2]. 
The new discovery that the major histocompati-
bility complex of class I (MHC I) expression in neu-
rons and glial cells has a novel function in the CNS, 
Ivyspring  
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represented an insight into understanding of the cross 
talk between neurons and glial cells. It is known that 
MHC I expression by neurons is not only important 
during development but also after lesion and during 
the course of neurological diseases. It has also been 
shown  to  influence  the  establishment  of  neuromus-
cular junctions, so that knock out mice that were un-
able to express MHC I molecules displayed morpho-
logical and functional alterations [3, 4].  
 A recent study has shown that MHC class I is 
expressed in axons and presynaptic terminals at skel-
etal neuromuscular junction level, especially in spinal 
cord motor neurons. Such expression is higher after 
axonal lesion in the peripheral nerve. In contrast, the 
absence of MHC I lead to a disturbed organization in 
neuromuscular junctions, suggesting that MHC I ef-
fects  could  be  mediated  by  Schwann  cells,  which 
present receptors to MHC I [5]. 
 Although the synaptic elimination in the spinal 
cord after lesion is possibly driven by motoneurons, 
astrocytes and microglia are also involved, both be-
cause of the intimate contact they have with the mo-
toneuron membrane surface and because they are able 
to express both MHC I and possible ligants to such 
complexes [6]. 
 Another recent study investigated the hypothe-
sis  that  synaptic  elimination  after  sciatic  nerve  ax-
otomy was also dependant on the MHC I expression 
[7]. In this sense, beta-2 microglobulin (a co-subunit of 
the MHC class I complex) deficient mice were sub-
jected to unilateral sciatic nerve crush or transection. 
As a result, the beta-2 microglobulin deficient animals 
showed  greater  synaptic  elimination,  and  an  ultra-
structural analysis showed that the inhibitory synap-
tic terminals were the most compromised, since non 
mutant axotomized animals showed a smaller reduc-
tion  in  inhibitory  terminals.  Another  study  on  the 
regenerative  capacity  and  MHC  I  expression  per-
formed  with  different  mice  strains  showed  that 
C57BL6/J mice naturally expressed reduced amounts 
of MHC I and had a lower regenerative potential and 
lower percentage of synaptic detachment after nerve 
injury  as  compared  to  A/J  mice,  which  expressed 
higher amounts of MHC I and had an increased re-
generative  capacity  coupled  with  a  greater  rate  of 
synaptic retraction post axotomy [8]. 
 The concept that MHC I is relevant to synaptic 
plasticity  after  lesion  was  also  strengthened  by  up-
regulating  its  expression  after  lesion  and  treatment 
with interferon beta, which is a cytokine used to treat 
the  remittent/recurrent  form  of  Multiple  Sclerosis 
(MS),  an  inflammatory/neurodegenerative  disease 
that affects the central nervous system (CNS) [9-11]. 
Experimental  autoimmune  encephalomyelitis  (EAE) 
is an animal model for (MS) and can be induced in 
monkeys,  pigs,  rats  or  mice.  Also  these  models  re-
produce the same mechanisms of demyelination and 
axonal  injury  [12-14].  The  disease  can  develop  in  a 
monophasic  form,  with  an  acute  paralysis  episode 
(onset),  followed  by  complete  recovery,  or  present 
relapsing/remitting episodes which involve multiple 
cycles of inflammation with partial recovery between 
exacerbations [13]. EAE induction in C57BL/6 mice 
with myelin oligodendrocyte glycoprotein (MOG35-55) 
has been  studied for several years, and it  has been 
shown that induced animals present territories with 
mononuclear  infiltrates  in  the  white  matter  of  the 
spinal cord, associated with local demyelination [14]. 
CD4 T cell activation is the major factor for EAE in-
duction, which is worsened by macrophage and mi-
croglia activation, resulting in tissue destruction and 
demyelination [15, 16]. The Inflammation and demy-
elination  are  reduced  when  mice  recover  from  the 
clinical signs and are therefore beginning to solve the 
histopathological changes [17]. 
 In addition to interferon beta, another substance 
that has been used with success to control the evolu-
tion  of  relapsing-remitting  MS  is  glatiramer  acetate 
(GA,  Copaxone),  which  is  an  immunomodulatory 
drug  composed  of  a  synthetic  polypeptide  mixture 
with  a  4  amino  acid  sequence  -  L-Glutamic  acid, 
L-lysine, L-alanine and L-tyrosine [18-20]. Although 
its action mechanism is still not fully understood, two 
possible  pathways  may  account  for  the  drug  effec-
tiveness. One indicates that GA promotes immuno-
regulatory  Th2  cell  activation,  driving  the  immune 
response  to  an  anti-inflammatory  response.  Also,  it 
has been shown that Th2 cells secrete important neu-
rotrophins for neural survival and axonal protection. 
In the second, GA may stimulate immune cells of local 
glial cells to secrete neurotrophins in the CNS terri-
tory. This may promote neuronal network repair and 
increase cell survival [21, 22]. In this sense, Marques et 
al. [21] showed that the GA treatment in Lewis rats 
subjected to EAE led to synaptic input preservation in 
the spinal cord during the onset of the disease and in 
the remission phase. Such effects were coupled with a 
decrease in the seriousness of the disease, indicating 
that synaptic network preservation may contribute to 
a reduction in the clinical signs of the disease.  
 Taking into account that GA immunomodulates 
different levels of the immune response and that the 
first  level  of  activity  is  on  the  MHC  complex,  it  is 
possible  that  its  action  also  influences  the  neuronal 
response to injury by competing with other ligants, 
possibly  provided  by  pre-synaptic  neurons  and/or 
glial cells. GA may also indirectly influence the syn-
aptic  plasticity  process  by  driving  the  immune  re-Int. J. Biol. Sci. 2011, 7 
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sponse  to  an  anti-inflammatory  profile,  contrary  to 
what  happens  after  lesion  or  during  the  course  of 
EAE. 
 In the present study evidence is presented that 
GA can influence the MHC class I expression and the 
synaptic plasticity process in the spinal cord during 
the course of remittent/recurrent EAE. Such changes, 
induced by GA treatment, involve neurons and glia 
and are possibly related to a downregulation of the 
MHC I expression in the spinal cord microenviron-
ment. 
Material and Methods 
Animals 
 Seventy adult female C57Bl/6 mice (6-8 weeks 
old, ~ 25g body weight) were obtained from the Mul-
tidisciplinary  Center  for  Biological  Investigation  of 
the  University  of  Campinas  /  SP  -  Brazil  (CEMIB ⁄ 
UNICAMP) and housed under a 12h light ⁄dark cycle 
with  free  access  to  food  and  water.  The  study  was 
approved by the Institutional Committee for Ethics in 
Animal  Experimentation  (CEEA/  IB/  UNICAMP, 
proc. 1316-1) and the experiments were performed in 
accordance with the guidelines of the Brazilian Col-
lege for Animal Experimentation.  
 The mice were allocated into three groups and 
each group was divided into two subgroups. The first 
group of mice (n= 30) was submitted to EAE, treated 
with placebo (n=15) or treated with GA (n=15) and 
sacrificed  when  presenting  paraplegia  (grade  3); 
whereas the second group of mice (n= 30) was also 
treated  with  placebo  (n=15)  and  treated  with  GA 
(n=15), but was sacrificed when the clinical signs de-
creased (~21 days) after the peak of the EAE (remis-
sion phase). A third group of mice (n=10) was used as 
the normal control and were not subjected to any ex-
perimental procedure. In all cases, after being sacri-
ficed, the spinal cords were processed either for an 
immunohistochemical examination, Western Blotting 
or for an ultrastructural analysis (n=5 for each group). 
Induction of experimental autoimmune en-
cephalomyelitis and GA treatment 
 All reagents were obtained from Sigma-Aldrich 
(St  Louis,  MO,  USA)  except  for  those  specifically 
mentioned. The mice were immunized with a single 
injection of 100 µl of myelin oligodendrocyte glyco-
protein  (MOG35-55)  associated  with  heat-inactivated 
Mycobacterium  tuberculosis  H37RA  (1.5  mg/mL; 
Difco Laboratories, Detroit, MI, USA) and complete 
Freund’s  adjuvant  emulsion.  This  solution  was  in-
jected subcutaneously into the base of the tail. Two 
Bortetella pertussis injections were then administered; 
one after the MOG injection and the second, 48 hours 
later. The treatment with GA (0.05mg/animal; batch 
n°  334190,  Teva,  Israel)  or  placebo  solution  was 
started 30 minutes after induction and was carried out 
subcutaneously on a daily basis. A daily analysis of 
the signs and symptoms of EAE severity was deter-
mined as follows: grade 0, no clinical signs; grade 1, 
tail weakness or paralysis; grade 2, hind limb para-
paresis; grade 3, hind limb paralysis; grade 4, com-
plete paralysis (tetraplegy). The animals were sacri-
ficed  14  days  after  induction  (exacerbation/onset 
group) and 21 days after induction (remission group).  
Specimen preparation  
 The animals were anesthetized with a mixture 
of Kensol (xylazine) and Vetaset (ketamine) and the 
vascular system rinsed by transcardial perfusion with 
phosphate  buffer  (pH  7.4).  For  the  immunohisto-
chemical  detection  of  synaptophysin,  glial  fibrillary 
acidic protein (GFAP) and microglia (Iba1), the mice 
were fixed by vascular perfusion with 4% paraform-
aldehyde in phosphate buffer (pH 7.4).  
 The lumbar intumescences were then dissected 
out, post-fixed overnight, washed in phosphate buffer 
and stored in sucrose (20%) for 8h before freezing.  
 For Western Blotting the vascular system of the 
mice  was  rinsed  by  transcardial  perfusion  with 
phosphate buffer (pH 7.4) without the use of a fixative 
solution.  The  lumbar  intumescences  were  dissected 
out and stored at -80°C. 
 For transmission electron microscopy, 100 ml of 
a  fixative  containing  2.5%  glutaraldehyde  and  0.5% 
paraformaldehyde in phosphate buffer (pH 7.4) were 
perfused through the ascending aorta, following the 
rinsing process described  above. The lumbar  spinal 
cords were removed and stored overnight in the same 
fixative  at  -4°C.  The  specimens  were  then  trimmed 
and  osmicated,  dehydrated  and  embedded  in  Dur-
cupan (Fluka, Steinheim, Switzerland). Ultra-thin sec-
tions  from  the  L4–L6  segments  were  collected  on 
formvar-coated copper grids, contrasted with uranyl 
acetate and lead citrate, and examined under a Leo906 
(Zeiss,  Germany)  transmission  electron  microscope 
operated at 60 kV. 
Immunohistochemistry 
 Transverse  sections  of  the  spinal  cord  (12  μm 
thick) were cut in a cryostat (Microm), transferred to 
gelatin coated slides and incubated with the following 
primary antibodies: rabbit anti-synaptophysin (Dako, 
1:100),  goat  antiglial  fibrillary  acidic  protein  (Santa 
Cruz, 1:200) and rabbit anti- Iba1 (Wako, 1:700). The 
sections were incubated overnight in a moist chamber 
at 4°C. The primary antisera were diluted in a solution Int. J. Biol. Sci. 2011, 7 
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containing bovine serum albumin (3%) and Triton X 
(0.2%) in 0.1m phosphate-buffer (PB). After rinsing, 
the secondary antibodies were applied and incubated 
for 45 min, according to the host of the primary anti-
bodies  (CY-2  and  CY-3,  Jackson  Immunoresearch, 
1:250). The sections were then rinsed in PB, mounted 
in a mixture of glycerol ⁄ PB (3:1) and observed under 
a  fluorescence  microscope  (TS-100,  Nikon,  Tokyo, 
Japan) equipped with a CCD camera (DMX1200, Ni-
kon). For quantitative measurements, 3 representative 
images of synaptophysin, glial fibrillary acidic protein 
and Iba1 immunoreactivity, from alternate sections of 
the L5 ventral horn, were captured for each animal of 
all the experimental groups, totaling 15 sampled im-
ages  for  each  group.  Quantification  was  performed 
with the enhance contrast and density slicing feature 
of the IMAGEJ software (version 1.33u, National In-
stitute of Health, USA). The integrated density of pix-
els was systematically measured in six representative 
areas of the lateral motor nucleus. The mean and SE 
were calculated for each group and a statistical anal-
ysis was performed. 
Western blotting 
 For total MHC class I quantification, 3mm of the 
lumbar spinal cords were cut out. The specimens were 
then sonicated for 1min in Rippa protein extraction 
buffer (150mM NaCl, 50 mM Tris pH 8.0, 1mM PMSF, 
1mM  EDTA,  0.5%  Na-deoxycholate  acid,  0.1%  SDS 
and 1% Triton X-100). The total protein concentration 
was  measured  using  the  Bio-Rad  Bradford  protein 
assay. 
 Western blotting was performed after the elec-
trophoresis of 30 to 80μg protein of each tissue sample 
on a 10% polyacrylamide gel under reducing condi-
tions,  and  electric  transfer  for  nitrocellulose  mem-
branes  (Hybond-ECL;  Amersham  Biosciences,  Chal-
font St. Giles, United Kingdom). The membranes were 
blocked  for  1h  with  1%  or  5%  non  fat  dry  milk  in 
TBS-T  (Tris  buffered  saline  plus  0.2%  Tween  20)  at 
room temperature with agitation. Rat anti-MHC class 
I  (ER-HR52  monoclonal  antibody,  Peninsula,  1:500, 
diluted in 1% nonfat dry milk in TBS-T,) rabbit and 
anti-CD11b  (BD  Pharmingen,  1:1000,  diluted  in  1% 
nonfat dry milk in TBS-T) , rabbit anti-GFAP (poly-
clonal antibody, Dako, 1:2000, diluted in 1% non fat 
dry  milk  in  TBS-T)  and  rabbit  anti-  Synaptophysin 
(monoclonal,  Dako,1:200,  diluted  in  5%  nonfat  dry 
milk in TBS-T) were incubated overnight at 4°C. After 
the primary antisera, three TBS-T washes were carried 
out, and then HRP conjugated rabbit anti-rat IgG and 
goat anti-rabbit IgG (1:2500, in TBS-T, Zymed Labor-
atories, San Francisco, CA, USA) added for 1h at room 
temperature  with  agitation.  After  another  set  of 
washes, detection of bound antigen was achieved by 
chemiluminescence  (Perkin-Elmer,  Waltham,  MA, 
USA). Band intensity was determined by densitome-
try  using  ImageJ  Software  (version  1.33u,  National 
Institute  of  Health,  USA).  Load  control  blotting  ex-
periments were performed with beta-actin (polyclo-
nal, 1:5000, Abcam, USA). 
Analysis of the ultra-thin sections 
 Neurons with large cell bodies (> 35 μm in di-
ameter) found in the sciatic motoneuron pool and cut 
in the nuclear plane, were identified as alpha moto-
neurons by the presence  of C-type nerve terminals. 
The surface of the cells was then sequentially digital-
ized at a magnification of 12,930 and 21,000 with a 
video  camera  connected  to  a  computerized  system, 
using  the  acquisition  feature  of  the  kontron  ks300 
software  (Zeiss).  Synaptic  terminals  apposing  the 
motoneuron somata were identified in the EAE ani-
mals treated with both placebo and GA. 
Statistical analysis 
 The  data  were  firstly  subjected  to  descriptive 
statistics and presented normal distribution. Statisti-
cal  differences  between  normal,  placebo  and  GA 
treated  groups  were  accessed  by  the  one  way 
ANOVA. Further intergroup comparisons were per-
formed with Student’s t test, assuming p<0.05 (*) and 
p<0.01 (**). The numerical results were presented as 
the mean ± se. 
Results 
Decreased MHC I expression after GA treat-
ment in EAE induced mice 
 The MHC I expression of the animals submitted 
to EAE and treated with GA can be seen in Figure 1, 
showing immunoreactivity in the spinal cord motor 
ventral nuclei. Figures 1 A and D show the normal 
animals  (control).  The  MHC  I  expression  changed 
drastically during the onset of the disease after EAE 
induction, and MHC I upregulation can be observed 
in Figure 1C for the animals treated with placebo. GA 
treatment resulted in a decreased expression for MHC 
I (Figure 1B). Figures 1 E-F represent the disease re-
mission phase, showing a decrease in the expression 
of MHC I in animals treated with GA (E) and with 
placebo (F). Also the clinical signs were milder at this 
stage than during exacerbation. The decrease in im-
munolabelling  for  MHC  I  after  GA  treatment  as 
compared to those treated with placebo and normal 
animals (control) was statistically significant during 
the exacerbation phase, as shown in Figure 1G (nor-
mal, 7.69 ± 1.08; placebo, 13.18 ± 0.93; GA treatment Int. J. Biol. Sci. 2011, 7 
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9.83 ± 0.83; Integrated density of pixels ×103; Mean ± 
SEM; p<0.05). The remission phase data can be seen in 
Figure 1H (normal, 7.69 ± 1.08; placebo, 10.0 ± 0.23; 
GA treatment, 8.32 ± 0.26; Integrated density of pixels 
×103; Mean ± SEM; p<0.05). 
 The quantitative MHC I protein expression by 
Western blotting can be seen in Figure 2. Figure 2 A 
shows the MHC I expression during exacerbation and 
Figure 2 B shows the MHC I expression during re-
mission. It can be seen that the MHC I expression in-
creased in both disease phases. The graph in C shows 
a  statistical  difference  between  the  groups  during 
exacerbation  (normal,  0.47±0.07;  treated,  0.93±0.17; 
placebo, 2.76±0.26, Integrated density of pixels ×103; 
Mean±SEM p <0.001). Note that the MHC I expression 
was lower in the remission stage and also the symp-
toms  were  reduced,  especially  in  the  GA  treated 
group. The statistical differences between the groups 
can be seen in graph D (normal, 0.89 ± 0.15, treated, 
0.95 ± 0.11, placebo, 1.60 ± 0.08, p <0.05, Integrated 
density of pixels ×103; Mean±SEM p <0.001). 
 
Figure 1 - MHC class I immunolabeling in the spinal cord ventral horn of C57BL/6 mice: normal (A and D), GA treated at 
the disease peak (B) and in the remission phase (E), and placebo treated at the disease peak (C) and in the remission phase 
(F). Note the low MHC I expression in the normal group and the overall increase in labeling in the placebo treated groups, 
especially at the disease peak. Quantification of the integrated density of pixels in each group is depicted in graphs G – 
disease peak and H – remission phase (*p<0.05, **p<0.01, ***p<0.001). Scale bar = 50m. Int. J. Biol. Sci. 2011, 7 
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Figure 2 – Western blotting of MHC class I expression (44KDa) within the lumbar intumescence in normal, placebo and 
GA treated mice at the disease peak (A) and during the remission phase (B). GA treatment resulted in a decreased MHC I 
expression in the motoneuron surroundings. Quantification of the bands is represented by graphs C and D for the disease 
peak and remission phase respectively (*p<0.05, **p<0.01, ***p<0.001). 
 
 
Loss of synaptophysin immunoreactivity after 
GA treatment 
 Figure 3 shows the immunoreactivity for syn-
aptophysin  in  the  spinal  cord  motor  ventral  nuclei. 
Figures 3 A and D represent normal animals with no 
disease. Figures 3 B and C show animals at the disease 
peak (onset), treated with GA and with placebo, re-
spectively. It was observed that animals treated with 
placebo  showed  greater  synaptic  loss  as  compared 
with GA treated animals, which showed less promi-
nent synaptic elimination. Figure 3G shows a statisti-
cal comparison between placebo and GA treated an-
imals at the disease peak and normal animals (normal, 
21.40 ± 0.49; placebo, 7.06 ± 0.81; GA treated, 15.37 ± 
0.69; Integrated density of pixels ×103; Mean ± SEM; 
p<0.05).  
 The animals in the disease remission stage are 
represented in Figure 2 E-F, where those treated with 
GA (E) and with placebo (F) showed an improvement 
in  immunolabeling  as  compared  to  the  peak  of  the 
disease, in line with the reduction in clinical signs and 
also the decrease in MHC I expression. Figure 4G and 
H shows the statistically significant increase in label-
ing in the GA treated group as compared to normal 
and  placebo  treated  groups  (normal,  21.40  ±  0.49; 
placebo,  11.91  ±  0.67;  GA  treated,  16.80±  0.43;  Inte-
grated density of pixels ×103; Mean± SEM; p<0.001).   Int. J. Biol. Sci. 2011, 7 
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Figure 3 - Synaptophysin immunolabeling in the spinal cord ventral horn of C57BL/6 mice: normal (A and D), GA treated 
at the disease peak (B) and in the remission phase (E), and placebo treated at the disease peak (C) and in the remission phase 
(F). Note the high synaptophysin expression in the normal group, particularly at the surface of the large motoneurons 
(arrows), and the overall decrease in labeling in the placebo treated groups, mostly at the disease peak. The GA treatment 
correlated with a significant preservation of inputs to the motoneuons at the disease peak. Quantification of the integrated 
density of pixels in each group is depicted in graphs G – disease peak and H – remission phase (*p<0.05, **p<0.01, 
***p<0.001). Scale bar = 50m. 
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Figure 4 - Western blotting of synaptophysin expression (38KDa) within the lumbar intumescence in normal, placebo and 
GA treated mice during the disease peak (A) and remission phase (B). GA treatment resulted in preservation of the syn-
aptophysin expression in the motoneuron surroundings, indicating that the treatment had a positive influence on the 
synaptic stability during the course of the disease. Quantification of the bands is represented in graphs C and D for the 
disease peak and remission respectively (*p<0.05, **p<0.01, ***p<0.001). 
 
 
The synaptophysin protein expression by West-
ern blotting showed a decrease in animals with EAE, 
Figure 4. Animals treated with GA in both phases of 
the  disease  analyzed  showed  better  preservation  of 
the synaptic covering when compared to the placebo 
treated mice. Such results indicated that GA admin-
istration had a positive influence on synaptic stability 
during the course of EAE. Figure 4 C illustrates the 
positive  statistical  differences  between  the  groups 
during the exacerbation phase (normal, 12.96 ± 0.66; 
treated, 11.94 ± 0.88; placebo, 8.68 ± 1.10; Integrated 
density of pixels ×103; p <0.05). In addition, Figure 4 
D  shows  the  difference  between  the  groups  at  the 
remission stage of the disease (normal, 18.24 ± 0.56; 
treated, 15.76 ± 0.78; placebo, 13.33 ± 0.68; Integrated 
density of pixels ×103; Mean±SEM; p < 0.01). 
 The immunohistochemical and Western blotting 
results were in line with the electron microscopy ob-
servations,  which  have  shown  a  general  better 
preservation of synapses apposed to alpha motoneu-
rons in the ventral horn. As seen in Figure 5, placebo 
treated animals presented a number of retracted pre 
synaptic terminals, what is less evident in GA treated 
specimens. 
Decrease in glial reaction in EAE induced an-
imals after treatment with GA  
 The reactivity of astrocytes may be measured by 
the  GFAP  expression.  Figure  6  shows  a  significant 
increase in GFAP during the exacerbation of the dis-
ease. The pattern of labeling in the control group is 
represented in Figure 6 A and D. The immunolabeling 
of samples from the animals treated with placebo is Int. J. Biol. Sci. 2011, 7 
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shown in Figures 6 C and E, and of those from GA 
treated animals in Figures 6 B and F. During the ex-
acerbation phase of the disease, the GFAP expression 
was elevated in animals treated with placebo, whilst 
the  GA  treated  animals  showed  a  decreased  GFAP 
expression. A significant increase in astrocyte reactiv-
ity  during  exacerbation  was  demonstrated  by  the 
presence of reactive astrogliosis in the CNS. GA ad-
ministration partially inhibited the glial response, as 
reflected in a decreased GFAP expression during the 
disease peak. The quantitative analysis is presented in 
Figure 6 G (normal, 4.83 ± 0.49; placebo, 13.14 ± 1.32; 
GA treated, 5.57 ± 0.97; Integrated density of pixels 
×103; Mean±SEM; p<0.01). 
 At  remission,  animals  treated  with  placebo 
showed a reduction in GFAP expression, indicating a 
decrease in local inflammation. Animals treated with 
AG still showed less astroglial reaction in comparison 
to the placebo treated group, as seen in Figure 6 H 
(normal, 4.83 ± 0.49; placebo, 9.78 ± 0.77; treated, 7.21 
± 0.37; Integrated density of pixels ×103; Mean±SEM; p 
<0.05). 
 The  protein  expression  of  reactive  astrocytes, 
GFAP,  obtained  by  Western  blotting  quantification, 
confirmed  the  immunolabeling  results,  and  showed 
an  increased  expression  of  this  protein  in  placebo 
treated animals as compared to GA treated and nor-
mal animals during the exacerbation phase (Figure 7). 
During the exacerbation phase there was a statistical 
difference between normal, GA treated and placebo 
treated animals (normal, 8.17 ± 0.84; GA treated, 8.35 ± 
0.57; placebo, 11.60 ± 0.70; Integrated density of pixels 
×103; p<0.05, Figure 7 C). The same picture was seen 
at the remission stage, since the placebo treated ani-
mals also expressed greater amounts of GFAP (nor-
mal, 7.53 ± 0.51; GA treated, 8.01 ± 0.53; placebo, 9.89 ± 
0.24; Integrated density of pixels ×103; p <0.05, Figure 
7 D).  
 
Figure 5 – The ultrastructure at the surface of 
the alpha motoneurons, showing synapses in 
apposition to the cell membrane. (A) Placebo 
treated  specimen  depicting  the  retraction  of 
terminals from the surface of a motoneuron. 
(B) A partially detached pre-synaptic terminal is 
shown in detail (arrow). (C) Preserved nerve 
terminals apposed to an alpha motoneuron at 
the disease peak, after treatment with GA. (D) 
Detail of a preserved input in almost complete 
apposition  with  the  motoneuron  plasma 
membrane  (arrow).  Note  the  presence  of 
active  electrondense  zones  in  the  synapse. 
Scale bar = 1m. 
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Figure 6 - GFAP immunolabeling in the spinal cord ventral horn of C57BL/6 mice: normal (A and D), GA treated at the 
disease peak (B) and remission phase (E), and placebo treated at the disease peak (C) and remission phase (F). Note the 
higher GFAP expression in the placebo treated group, particularly in the surroundings of the large motoneurons, and the 
overall decrease in labeling in the GA treated groups, particularly at the disease peak. Quantification of the integrated density 
of pixels in each group is depicted in graphs G –disease peak and H – remission phase. Scale bar = 50m. Int. J. Biol. Sci. 2011, 7 
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Figure 7 - Western blotting of GFAP expression (50KDa) within the lumbar intumescence in normal, placebo and GA 
treated mice during the disease peak (A) and remission phase (B). The GA treatment kept astrogliosis close to the normal 
degree, whereas the placebo group showed a significant increase in this protein both at the disease peak and in the remission 
phase. Quantification of the bands is represented in graphs C and D for the disease peak and remission phase respectively 
(*p<0.05, **p<0.01, ***p<0.001). 
 
 
 The microglial reaction of the spinal cord area 
surrounding  the  alpha  motoneurons  increased,  as 
depicted by the immunohistochemistry examination. 
Immunolabeling  against  Iba1  is  shown  in  Figure  8. 
Figures 8 A and D display the control animals, while 
Figures 8 C and F show the placebo treated sections 
during  the  exacerbation  and  remission  phases.  Fig-
ures 8 B and E represent specimens from GA treated 
animals during the exacerbation and remission phas-
es,  respectively.  During  the  exacerbation  phase,  the 
GA treatment was able to reduce the reactivity of the 
microglia as compared to the placebo group (normal, 
3.58 ± 0.24; placebo, 19.54 ± 0.97; GA treated, 6.88 ± 
1.15, Integrated density of pixels ×103; Mean±SEM; p 
<0.01). The remission phase showed a decrease in Iba1 
expression in the placebo treated group (Figure 8F). 
The  GA  treated  group  presented  greater  microglial 
expression at this stage than during the exacerbation 
(normal, 3.58 ± 0.24; placebo, 8.44 ± 0.39; GA treated, 
6.58  ±  0.30,  Integrated  density  of  pixels  ×103; 
Mean±SEM p <0.001). 
 The  protein  expression  of  reactive  microglia, 
relative to CD11b labeling, obtained by Western blot-
ting  quantification,  confirmed  the  immunolabeling 
results, and showed an increased expression of this 
protein in placebo treated animals as compared to GA 
treated and normal animals during the exacerbation 
phase (Figure 9). During the exacerbation phase there 
was  a  statistical  difference  between  normal,  GA 
treated and placebo treated animals (normal, 4.96 ± 
0.28; GA treated, 5.93 ± 0.21; placebo, 7.66 ± 0.26; In-
tegrated density of pixels ×103; p <0.05, Figure 9 C). Int. J. Biol. Sci. 2011, 7 
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However,  during  the  remission  stage,  no  statistical 
differences  were  depicted  between  groups  (normal, 
4.83 ± 0.69; GA treated, 4.24 ± 0.19; placebo, 5.19 ± 
0.23; Integrated density of pixels ×103; p <0.05, Figure 
9 D).  
 
 
Figure 8 – Iba1 immunolabeling in the spinal cord ventral horn of C57BL/6 mice: normal (A and D), GA treated at the 
disease peak (B) and in the remission phase (E), and placebo treated at the disease peak (C) and in the remission phase (F). 
Note the higher Iba1 expression in the placebo treated group, particularly in the surroundings of the large motoneurons, and 
the overall decrease in labeling in the GA treated groups, particularly at the disease peak. Quantification of the integrated 
density of pixels in each group is depicted in graphs G – disease peak and H – remission phase. Scale bar = 50m. 
 
 Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
1200 
 
Figure 9 - Western blotting of the Iba-1 expression (95, 165-170KDa) within the lumbar intumescence in normal, placebo 
and GA treated mice during the disease peak (A) and remission phase (B). GA treatment kept the microglial reaction at a 
level close to normal, whereas the placebo group showed a significant increase in this protein both at the disease peak and 
in the remission phase. In the remission phase no differences between groups were depicted. Quantification of the bands is 
represented in graphs C and D for the disease peak and remission, respectively (*p<0.05, **p<0.01, ***p<0.001). 
 
Discussion 
 Multiple  sclerosis  is  a  chronic  disease  that  af-
fects a significant number of individuals usually at a 
very active age. The evolution of the disease involves 
a series of changes in the immune response so that an 
initially  remittent/recurrent  form  may  evolve  to  a 
progressive state within a few years  [22]. Not until 
recently has it become accepted that the worsening of 
MS  also  involves  a  neurodegenerative  process  that 
may be present from the beginning, but seems to be 
subclinical, due to adaptive changes in the CNS that 
include synaptic plasticity and bypassing of ascend-
ing or descending pathways. The occurrence of such 
changes  was  reinforced  by  the  work  of  Kerschen-
steiner et al. [23] with the use of an animal model of 
MS,  namely  experimental  autoimmune  encephalo-
myelitis (EAE). In this work it was demonstrated that 
axons remodel at multiple levels in response to a sin-
gle  neuroinflammatory  lesion.  Such  plasticity  in-
cluded  local  changes  in  the  spinal  cord  as  well  as 
modification in the corticospinal tract and in the mo-
tor cortex. 
 In a previous study, important network changes 
in  the  spinal  cord  of  EAE  induced  rats  during  the 
course of the disease were also demonstrated [24]. The 
morphological  changes,  especially  in  the  surround-
ings of the alpha spinal motoneurons, correlated with 
the worsening of the clinical signs of the disease and 
with the recovery from paralysis. In the present work, Int. J. Biol. Sci. 2011, 7 
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such changes were studied along with the expression 
of the MHC I complex, that has recently been impli-
cated as part of a mechanism of synaptic plasticity.  
 The  present  results  provide  evidence  that  the 
MHC  I  expression  is  enhanced  in  the  spinal  cord 
during onset of the disease, and is concentrated in the 
surroundings of the motoneurons. As shown by Fre-
ria et al. [25] the motoneurons themselves, as well as 
glial cells, upregulate the expression of MHC I mRNA 
during the peak disease, coinciding with the period of 
greater synaptic remodeling. In the present study, the 
cytoplasmic MHC I protein expression could not be 
shown in the motoneurons, which possibly indicated 
a  low  level  of  nRNA  translation.  Nevertheless, 
knocking out the MHC I expression altered the pat-
tern of synaptic elimination during development and 
after a peripheral nerve lesion [4, 25] so that, even at 
low levels, neuronal MHC I is of importance during 
plasticity of the synapses. 
 As  shown  by  the  immunohistochemical  and 
Western  blotting  analyses,  the  GA  treatment  corre-
lated with a decreased expression of MHC I during 
the induction phase of the disease. GA may also bind 
to the neuronal as well as to the glial MHC molecules 
expressed  within  the  CNS.  This  may  influences 
communication  between  such  cells,  contributing  to 
the decreased loss of inputs to the motoneurons dur-
ing the peak disease. Such preservation of inputs was 
depicted  by  the  synaptophysin  immunolabeling, 
transmission  electron  microscopy  of  the  area  sur-
rounding the alpha spinal motoneurons, as well as by 
Western  blotting  analysis.  These  results  also  corre-
lated  with  the  less  intense  clinical  signs  during  the 
course of the disease.  
 The positive action of GA during the course of 
EAE  was  previously  reported  with  respect  to  the 
prevention of the demyelination typical of untreated 
induced  animals.  The  ultrastructural  analysis  re-
vealed  that  even  if  GA  therapy  was  initiated  after 
onset of the disease, the loss of myelin could be re-
duced. A possible induction of remyelination was also 
proposed.  Altogether,  it  is  possible  to  hypothesize 
that GA targets different processes in the CNS during 
the course of the disease, including modulation of the 
MHC I and its effects on the synapses in the spinal 
cord. 
 The GA treatment was also able to reduce gliosis 
during  the  peak  disease,  as  seen  by  the  GFAP  (for 
astrocytes)  and  Iba1  (for  microglia)  analyses.  These 
results are in line with the putative anti-inflammatory 
effects of GA by inducing Th2/3 cells, which secrete 
IL-4, IL-10 and transforming growth factor, but not 
Th1 related cytokines. Glial cells have been implicated 
in both positive and negative events that develop after 
neurological damage and disease [26-28]. It is possible 
that  reactive  astrocytes  as  well  as  microglia  secrete 
pro-inflammatory  substances  that,  in  turn,  increase 
synaptic lesion and retraction, decreasing the regen-
erative potential and survival of the neurons. Never-
theless, under an anti-inflammatory stimulus, such as 
GA treatment, they may secrete trophic factors and 
other substances that may be neuroprotective as well 
as stabilizing the neuronal circuits. The increase in the 
microglia reaction after GA treatment in the remission 
phase may be related to such a protective response, 
since it did not interfere in the synaptic covering, as 
shown by synaptophysin immunolabeling and by the 
ultrastructural analysis. 
 The idea that immunomodulating the evolution 
of  the  disease  could  also  positively  reflect  on  the 
synapses and glial cells in the CNS, may also apply to 
other situations such as mechanical damage. In this 
sense, Piehl et al. [26] and Barbizan & Oliveira [29] 
described  a  neroprotective  effect  of  inflammation 
during the peak of EAE, if combined with ventral root 
avulsion.  It  was  also  demonstrated  an  increase  in 
BDNF  mRNA  and  protein  expression  within  the 
damaged neuropil, which possibly accounted for the 
increase in neuronal survival [28].  
 Further studies are necessary in order to inves-
tigate the outcome of CNS and PNS regeneration after 
repair  combined  with  GA  treatment.  A  thorough 
analysis of the glial response as well as a comparison 
of the secreted cytokines and trophic factors after GA 
treatment,  may  also  contribute  to  a  better  under-
standing of such immunomodulatory treatment. 
 In summary, the present results show that the 
GA treatment may decrease synaptic loss during the 
course of EAE, which correlates with downregulation 
of the MHC I complex, recently implicated as a par-
ticipant during the rewiring of the nervous system. 
Also,  the  decrease,  but  not  the  absence,  of  the  as-
troglial  response  indicates  a  possible  an-
ti-inflammatory effect of the GA treatment, that stim-
ulates secretion of trophic factors and Th2 related cy-
tokines both by immune and glial cells. 
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